含雷替曲塞方案治疗进展期结直肠癌的临床观察  

Clinical observation of raltitrexed containing regimen for advanced colorectal cancer

作　　者：陈玲[1] 郭增清[1] 王晓杰[1] 陈誉[1] 余家密[1] 

机构地区：[1]福建省肿瘤医院肿瘤内科,福州350014

出　　处：《国际肿瘤学杂志》2017年第8期583-586,共4页Journal of International Oncology

摘　　要：目的 观察含有雷替曲塞的方案二线及多线治疗进展期结直肠癌的临床疗效和不良反应.方法 42例进展期结直肠癌患者接受含有雷替曲塞的方案化疗.评价患者的客观缓解率（ORR）、疾病控制率（DCR）、中位无进展生存时间（mPFS）和不良反应.结果 42例患者的ORR为16.67％,DCR为80.96％,mPFS为4.90个月（95％ CI为2.99 ～6.81个月）.大部分患者不良反应为Ⅰ～Ⅱ度,包括白细胞减少（30.95％）、血小板减少（2.38％）、血红蛋白减少（40.48％）、恶心呕吐（2.38％）、食欲减退（4.76％）、腹泻（2.38％）、转氨酶升高（47.62％）、乏力（11.90％）.只有4.76％的患者出现Ⅲ～Ⅳ度转氨酶升高.结论 含有雷替曲塞的方案二线及多线治疗进展期结直肠癌临床疗效肯定,患者耐受性好,值得临床上推荐使用.Objective To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment.Methods A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen.The objective response rate （ORR）,disease control rate （DCR）,median progression-free survival （mPFS） and adverse reactions were evaluated.Results The ORR of the 42 patients was 16.67%,DCR was 80.96%,and mPFS was 4.90 months （95% CⅠ：2.99-6.81 months）.The most of adverse reactions were grade Ⅰ-Ⅱ,including leucopenia （30.95%）,thrombocytopenia （2.38%）,anemia （40.48%）,nausea and vomiting （2.38%）,anorexia （4.76%）,diarrhea （2.38%）,transaminase elevation （47.62%） and fatigue （11.90%）.Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76% of patients.Conclusion Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated,and further clinical application is recommended.

关 键 词：结直肠肿瘤 药物疗法 雷替曲塞 

分 类 号：R735.34[医药卫生—肿瘤]